Finding
Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial
xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage
DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny
Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension
Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro
Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction
Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist
Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement
Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs
Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%
Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry
Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease
Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.
Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials
Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist
Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities
Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health